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Alzheimer’s disease is a type of dementia that causes memory, thinking, and behavior 
problems usually in people that are 65 or older [1]. It is the sixth leading cause of death in the 
United States and has affected over 26 million people worldwide [1][2]. In 2050, this number is 
predicted to increase to 106 million [2]. The cause of Alzheimer’s disease are the deposits of 
Amyloid-Beta (Aβ) protein fragments and the twisted fibers of tau proteins. These proteins 
build up inside the brain inducing the destruction and death of nerve cells which eventually 
results in symptoms such as memory failure, personality changes and more [1]. To find a 
treatment for this disease, many studies have relied on using potential modulators to prevent 
the formation of the plaques and find potential cures.  
Current studies have been able to discover many chemicals that can act as an inhibitory 
agent to prevent the formation of plaques in the brain cells. Kim and his group measured Alpha2 
receptor sites to observe the integrity of noradrenergic system in patients with Alzheimer’s 
disease and found that in subjects with Alzheimer’s disease, there was a significant reduction 
in norepinephrine (NE) concentration [3]. In another study, Heneka and his group performed an 
in-vivo study using mice and discovered that there was an increase in Aβ in NE—depleted mice 
[4]. However, much of the studies performed in-vivo and in-vitro are focused on observing the 
inhibitory effects that these chemicals have on the Aβ protein and not much explanation is 
given on the exact mechanisms with which these modulators are able to achieve such results. 
Therefore, a lot of research in the molecular dynamics simulation field is being done to better 
explain the interaction between potential inhibitors and Aβ proteins.  
To our knowledge, no molecular dynamics simulation has been done on norepinephrine 
to investigate the interaction with Aβ proteins. Hence, the purpose of this study is to observe 
and determine the exact mechanism involved in the interaction between 3,4-
dihydroxymandelic acid (DHMA), normetanephrine (NMN), which are metabolites of 
norepinephrine, and amyloid-beta protein through molecular dynamics simulations.  
This research has implications for determining potential drugs that are able to interact 
with Aβ and reduce the protein’s aggregating characteristics. Gathering more data on other 
types of modulatory drugs will better explain how Aβ protein accumulation can be reduced. 
Furthermore, this research can contribute to current research on Alzheimer’s disease and in the 




Increasing research evidence suggests that amyloid-beta (Aβ) protein misfolding and 
aggregation lead to Alzheimer’s disease (AD), a neurodegenerative disease. Accordingly, much 
of the current research involves discovering potential substances that could prevent aggregation 
and in turn observe the mechanisms involved during the process.  As more research is 
performed on Aβ, it would be possible to hinder the progression of AD and to even completely 
cure it in the near future.  
Although the exact mechanism is not fully understood, it is known that Aβ proteins, 
which are helical in their native states, gradually conform into beta-sheet structures and set the 
ground for the proteins to aggregate and form fibrils that are toxic. These fibrils are associated 
with Alzheimer’s disease. Nerelius et al.[5] investigated the relationship between the α-helical 
forms of Aβ and neurotoxicity by using ligands to stabilize the helix. Inhibitor ligands, Dec-
DETA and Pep1a, were designed to specifically bind to the α-helix of the peptide by using two 
methods: in-vitro and in-vivo. In vitro method involves incubating PC12 cells with Aβ proteins 
and the ligands, while in-vivo method is fulfilled by feeding transgenic flies with ligand 
containing fly food. From the experiment, the research group was able to conclude that when 
Dec-DETA and Pep1a were administered, the α-helical structure of the Aβ protein was retained 
and consequently, toxicity was reduced in both in-vitro and in-vivo. On the other hand, Simmon 
et al. [6] investigated the effects that beta-sheet structures have on the cytotoxicity of neuronal 
cells. The group incubated Aβ for several days in aqueous solution to let the protein gradually 
unravel from a helical structure to a β-sheet structure. Then, using the knowledge that the 
aggregation of the protein is dependent on the β-sheet formation, they measured the toxicity 
and found that there was a positive correlation between β-sheet structure content and toxicity 
in hippocampal cells. Due to the combined efforts of several researchers, the effects of the 
conformational changes of the Aβ protein have been relatively understood. However, the 
effects and mechanisms that external factors, such as antibodies and chemicals, have on the 
protein have not been fully explained. Therefore, much of the current research focuses on 
investigating potential modulators that can prevent Aβ protein aggregation.  
Amongst numerous approaches that scientists are taking to find the effects of 
introducing an external factor to amyloid beta proteins, is antibody administration. The 
antibodies are able to enter the central nervous system, decorate the plaques formed by the 
fibrils and induce clearance of preexisting amyloid. Bard et al. [7] intravenously administered 
10D5 and 3D6 antibodies to determine whether the antibodies against Aβ had entered the 
central nervous system and acted directly on the plaques. Through the ex-vivo assay of cryostat 
section of PDAPP mouse and human AD brains, the group was able to conclude that the 
antibodies against Aβ peptide greatly reduced the plaque deposition and that the entry to the 
central nervous system was not due to abnormal leakage of the blood-brain barrier. 
Administration of the antibodies itself is not the only way of targeting Aβ fibrils. Research has 
shown that human immunoglobulin contains antibodies against Aβ, which are able to recognize 
Aβ peptides and reduce Aβ toxicity, as well as inhibit Aβ fibrillation. Consequently, Dodel et 
al.[8] carried out an experiment on patients with AD by treating them with human 
immunoglobulin (IVIG) for six months. Through the results, the group found out that IVIG 
was able to reduce the Aβ concentration in the CSF and conclude that immunoglobulin has the 
potential to cure Alzheimer’s disease. Antibodies have higher specificity to the target, hence a 
higher efficacy and less side effects can be expected when treating AD [9]. However, the 
invasive intravenous administration and the high costs encourage researchers to find alternative 
substances for cure.  
The use of chemical substances, as opposed to antibodies to target Aβ proteins, is 
increasing due to the ease of handling the substances and the use of simpler materials and 
experiment methods. Wong et al.[10] and his research team used Erythrosine B (ERB) as an Aβ 
modulator to observe the inhibitory capabilities of the molecule. ERB is a FDA-approved 
xanthene type of food dye that exhibits no toxicity even at large doses. The Aβ sample was 
prepared and diluted in the absence or presence of ERB and ThT fluorescence assay, dot-
blotting as well as 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
reduction assay were performed to obtain the results. Although the research team was able to 
conclude that ERB inhibits the formation of Aβ fibrils and therefore prevents aggregation, the 
exact mechanism involved during this process is currently speculated and not fully understood. 
Hence, molecular dynamics simulations are performed to better comprehend how such 
molecules interact with the Aβ protein and ultimately understand its process. As reported by 
Yang et al.[11], a molecular dynamics simulation was conducted using Leu-Pro-Phe-Phe-Asp 
(LPFFD) with Aβ peptides. LPFFD is one of the many beta sheet breakers that are designed to 
prevent the formation of β-sheet structures and amyloid aggregation. The group obtained the 
protein structures from the Protein Data Bank (11YT) and carried out automated molecular 
docking using Autodock 4. Finally, the simulation was performed using GROMACS 3.3.3. MD 
package with the GROMOS96 43A1 force field. From the results obtained from the simulation, 
the group found out that LPFFD binds to the C-terminus of the Aβ proteins to prevent the α-
helical structure from conforming into a β-sheet structure. Additionally, LPFFD forms 
hydrogen bonds with the protein structure to stabilize the Aβ and therefore prevent aggregation. 
Running computer simulations is perhaps the best way to fully understand the mechanism 
involved in the interactions of various substances with Aβ protein. That is why the use of 
computer simulations to discover the solutions to well-known diseases, such as Alzheimer’s 
disease is growing.  
Most of the research on the prevention of amyloid-beta peptide aggregation involves 
testing different kinds of substances of different concentrations to see if an inhibitory effect 
can be observed. However, at the same time, most of these experiments do not explain the 
aggregation process that is involved. Therefore, the current study focuses on identifying these 
mechanisms, especially the interaction of 3,4-Dihydroxymandelic Acid (DHMA) and 
normetanephrine (NMN) with amyloid-beta, through computational simulations based on in-
vitro experimental results obtained from New York University. The simulation uses Cerius2, 
Jaguar, Autodock, and Gromacs to obtain the results that will explain how DHMA and NMN 
act as modulators. This newly acquired information will help understand Aβ aggregation 
better and act as a stepping stone to determine other substances that might have an inhibitory 




MATERIALS AND METHODS 
The amyloid beta proteins were taken from the PDB Bank online (Pdb ID: 1BA4). The 
norepinephrine metabolites, DHMA and NMN, were created using the graphical molecular 
modelling program Cerius2. DHMA and NMN were then run through Jaguar for density 
functional analysis (DFT) and charge optimization using the following conditions: Functional 
theory: B3LYP, Basis: 6-31G, Charge Analysis: Mulliken, Total Charge: -2, and Spin 
Multiplicity: 1. Next, to calculate the rough binding sites of DHMA and NMN on the amyloid 
beta protein AutoDock was used. Finally, the MD simulation and analysis were performed 














4.1 Aβ-DHMA Complex 
In order to perform a visual comparison between the structure of the protein without and with 
the drug, snapshots of the protein with and without the compound were taken at 4 different 
time pointes shown in Figure 1 and Figure 2. Without the drug, at 0 nanoseconds the Aβ protein 
retained its normal alpha helical structure, at 50 and 100 nanoseconds the protein gradually 
started to straighten and uncoil and finally at 150 nanoseconds the Aβ protein completely lost 
its helical structure. With the addition of the drug, at 0 nanoseconds the Aβ protein is at its 
helical structure, at 50 and 100 nanoseconds the Aβ protein gradually loses its helical structure 






















Figure 1 Aβ protein structure. The change in 
morphology of the protein at four different time 
points, 0ns (top left), 50ns (top right), 100ns 





4.2 Conformational Change of Backbone During MD Simulation 
The Root Mean Square Deviation (RMSD) analysis was performed to observe the change in 
the structure of backbone of the Aβ protein with and without DHMA through time as shown 
in Figure 3 and Figure 4. The RMSD of the Aβ protein with decreased compared to the 
RMSD value of the Aβ protein alone, indicating that DHMA was effective in minimizing the 
deformation of the protein.  
 
Figure 2 Aβ-DHMA complex. The change in morphology of the  
protein with DHMA at four different time points, 0ns (top left), 
50ns (top right),  
100ns (bottom left), 150ns (bottom right), is shown. 












4.3 Secondary Structure Change of Aβ40 Residues 
The Define Secondary Structure of Protein (DSSP) analysis was performed to observe the 
change in the secondary structures of the 40 residues present in the Aβ protein through 150 
nanoseconds as shown in Figure 5 and Figure 6. Without DHMA, most of the alpha-helix of 
the protein was lost at around 70 nanoseconds and beta-sheets started to form around 90 
nanoseconds. When DHMA was present, the residues of the protein started to uncoil as seen 
from the decrease of the alpha-helical structure while at the same time the drug was able to 
prevent the formation of the beta-sheet structures.  
 
Figure 5 DSSP Analysis of Aβ40 without DHMA 
Figure 4 Time averaged distance between Aβ with DHMA.  
 




5.1 Aβ-DHMA Complex 
The change in the protein structure reveals that when the Aβ protein is by itself, it loses much 
of its helical structure and gradually unravels during the 150 nanoseconds duration of the 
simulation as observed in Figure 1. On the other hand, when DHMA is added to the Aβ 
protein, the protein is able to retain parts of its helical structure as shown in Figure 2. The 
retention of this alpha-helix is an indication that DHMA is an effective compound in 
preventing the formation of protein oligomers which are thought to be the main cause of 
Alzheimer’s disease.  
5.2 Conformational Change of Backbone During MD Simulation 
The RMSD analysis shows that when DHMA is added to the Aβ protein its RMSD value 
decreases to about 0.6nm compared to just when the Aβ protein is present. This indicates that 
the backbone of the Aβ protein with DHMA had a fewer conformational change meaning that 
it was able to keep its alpha helical structure better. By retaining more of the alpha-helix, 
DHMA was able to prevent the transition of the Aβ protein from a helical structure to a beta-
sheet structure, which prevented the formation of oligomers that are hypothesized to be the 
cause of Alzheimer’s disease.   
5.2 Conformational Change of Backbone During MD Simulation 
The DSSP analysis shows that when the Aβ protein is by itself, the secondary structure of its 
residues start to uncoil, losing the alpha-helix which are indicated by the blue bands, and start 
to form beta-sheet structures which are indicated by the red bands. The formation of the beta-
sheets is what ultimately leads to the formation of the fibrils that are thought to cause plaques 
that result in Alzheimer’s disease. On the other hand, when DHMA is present although the Aβ 
protein loses most of its alpha helical structures, the drug does prevent the formation of the 
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